Abstract
There is a new and important disease that needs to be considered for MR imaging of the paediatric urogenital tract: nephrogenic systemic fibrosis (NSF). This entity, also known as nephrogenic fibrosing dermopathy or scleromyxedema-like illness of renal disease, is a recently defined condition with potentially deleterious outcome; its aetiology is not completely understood yet. A common factor is a kidney disease with renal insufficiency (on dialysis) or patients with liver transplants. Another factor observed in the majority of cases is gadolinium (Gd) administration, though there are patients suffering from NSF without previous known Gd exposure. Additional risk factors are metabolic acidosis and inflammatory and post-operative conditions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsFurther Reading
Auron A, Shao L, Warady BA (2006) Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 21:1307–1311
Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27–30
Broome DR, Girgius MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 188:586–592
Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris STW, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245:168–175
Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790
Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763–765
Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264–267
Dharnidharka VR, Wesson SK, Fennell RS (2007) Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19:467–470
Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108 (Erratum in: Nephrol Dial Transplant 21:1745)
High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710–712
Jain SM, Wesson S, Hassanein A, Canova E, Hoy M, Fenell RS, Dharnidharka VR (2004) Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19:467–470
Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143:678–681
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SB (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647–649
LeBoit PE (2003) What nephrogenic fibrosing dermopathy might be. Arch Dermatol 139:928–930
Leiner T, Herborn CU, Goyen M (2007) Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 17:1921–1923
Mackay-Wiggan JM, Cohen DJ, Hardy MA Knobler EH, Grossmann ME (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48:55–60 (Comment in: J Am Acad Dermatol 2006; 52:166–167)
Maloo M, Abt P, Kashyap R, Younan D, Zand M, Orloff M, Jain A, Pentland A, Scott G, Bozorgzadeh A. (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant; 6:2212–2217
Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362
Mendichovszky IA, Marks SD, Simcock CM, Olsen OE (2007). Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol, in press DOI 10.1007/s00247-007-0633-8
Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:73–76
Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Diamali A (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157
Steen H, Schwenger V (2007) Good MRI images: to Gad or not to Gad? Pediatr Nephrol 22:1239–1242
Thomsen HS, Morcos SK (2003) Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 76:513–518
Thomsen HS (2007) ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17:2692–2696
Thomsen HS, Marckmann P, Logager VB (2007) Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7:130–137
Thomsen HS, Marckmann P, Logager VB (2007) Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 48:593–596
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Riccabona, M., Dacher, JN., Olsen, Ø.E., Claudon, M., Fotter, R. (2008). Gadolinium and Nephrogenic Systemic Fibrosis. In: Fotter, R. (eds) Pediatric Uroradiology. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33005-9_29
Download citation
DOI: https://doi.org/10.1007/978-3-540-33005-9_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-33004-2
Online ISBN: 978-3-540-33005-9
eBook Packages: MedicineMedicine (R0)